These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37253281)

  • 41. Updates in Drug Treatment of Severe Hypertriglyceridemia.
    Gouni-Berthold I; Schwarz J; Berthold HK
    Curr Atheroscler Rep; 2023 Oct; 25(10):701-709. PubMed ID: 37642858
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia.
    Baass A; Paquette M; Bernard S; Hegele RA
    J Intern Med; 2020 Apr; 287(4):340-348. PubMed ID: 31840878
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypertriglyceridaemia: an update.
    Wierzbicki AS; Kim EJ; Esan O; Ramachandran R
    J Clin Pathol; 2022 Dec; 75(12):798-806. PubMed ID: 35710321
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis.
    Hernandez P; Passi N; Modarressi T; Kulkarni V; Soni M; Burke F; Bajaj A; Soffer D
    Curr Atheroscler Rep; 2021 Sep; 23(11):72. PubMed ID: 34515873
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.
    Rocha NA; East C; Zhang J; McCullough PA
    Curr Atheroscler Rep; 2017 Nov; 19(12):62. PubMed ID: 29124482
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Severe hypertriglyceridemia: Existing and emerging therapies.
    Malick WA; Do R; Rosenson RS
    Pharmacol Ther; 2023 Nov; 251():108544. PubMed ID: 37848164
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes.
    Digenio A; Dunbar RL; Alexander VJ; Hompesch M; Morrow L; Lee RG; Graham MJ; Hughes SG; Yu R; Singleton W; Baker BF; Bhanot S; Crooke RM
    Diabetes Care; 2016 Aug; 39(8):1408-15. PubMed ID: 27271183
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Familial Chylomicronemia Syndrome: A Clinical Guide For Endocrinologists.
    Falko JM
    Endocr Pract; 2018 Aug; 24(8):756-763. PubMed ID: 30183397
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia.
    Wierzbicki AS; Viljoen A
    Expert Opin Biol Ther; 2016 Sep; 16(9):1125-34. PubMed ID: 27248482
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins.
    Visser J; van Zwol W; Kuivenhoven JA
    Curr Atheroscler Rep; 2022 Jan; 24(1):1-12. PubMed ID: 35107764
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metabolism and Disposition of Volanesorsen, a 2'-
    Post N; Yu R; Greenlee S; Gaus H; Hurh E; Matson J; Wang Y
    Drug Metab Dispos; 2019 Oct; 47(10):1164-1173. PubMed ID: 31350288
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy.
    Lightbourne M; Startzell M; Bruce KD; Brite B; Muniyappa R; Skarulis M; Shamburek R; Gharib AM; Ouwerkerk R; Walter M; Eckel RH; Brown RJ
    J Clin Lipidol; 2022; 16(6):850-862. PubMed ID: 36195542
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Spectrum of Mutations and Long-Term Clinical Outcomes in Genetic Chylomicronemia Syndromes.
    D'Erasmo L; Di Costanzo A; Cassandra F; Minicocci I; Polito L; Montali A; Ceci F; Arca M
    Arterioscler Thromb Vasc Biol; 2019 Dec; 39(12):2531-2541. PubMed ID: 31619059
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study.
    Davidson M; Stevenson M; Hsieh A; Ahmad Z; Roeters van Lennep J; Crowson C; Witztum JL
    J Clin Lipidol; 2018; 12(4):898-907.e2. PubMed ID: 29784572
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis.
    Pedersen SB; Langsted A; Nordestgaard BG
    JAMA Intern Med; 2016 Dec; 176(12):1834-1842. PubMed ID: 27820614
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Spectrum of mutations of the LPL gene identified in Italy in patients with severe hypertriglyceridemia.
    Rabacchi C; Pisciotta L; Cefalù AB; Noto D; Fresa R; Tarugi P; Averna M; Bertolini S; Calandra S
    Atherosclerosis; 2015 Jul; 241(1):79-86. PubMed ID: 25966443
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors.
    Spagnuolo CM; Hegele RA
    Expert Opin Pharmacother; 2023 Jun; 24(9):1013-1020. PubMed ID: 37114828
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C-II.
    Fojo SS; Brewer HB
    J Intern Med; 1992 Jun; 231(6):669-77. PubMed ID: 1619390
    [TBL] [Abstract][Full Text] [Related]  

  • 59. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
    Schmitz J; Gouni-Berthold I
    Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Heparin and insulin in the treatment of acute hypertriglyceridemia-induced pancreatitis].
    Henzen C; Röck M; Schnieper C; Heer K
    Schweiz Med Wochenschr; 1999 Sep; 129(35):1242-8. PubMed ID: 10499250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.